MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling

Basak Icli, A. K.M. Wara, Javid Moslehi, Xinghui Sun, Eva Plovie, Meghan Cahill, Julio F. Marchini, Andrew Schissler, Robert F. Padera, Jianru Shi, Hui Wen Cheng, Srilatha Raghuram, Zoltan Arany, Ronglih Liao, Kevin Croce, Calum Macrae, Mark W. Feinberg

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

RATIONALE: The rapid induction and orchestration of new blood vessels are critical for tissue repair in response to injury, such as myocardial infarction, and for physiological angiogenic responses, such as embryonic development and exercise. OBJECTIVE: We aimed to identify and characterize microRNAs (miR) that regulate pathological and physiological angiogenesis. METHODS AND RESULTS: We show that miR-26a regulates pathological and physiological angiogenesis by targeting endothelial cell (EC) bone morphogenic protein/SMAD1 signaling in vitro and in vivo. MiR-26a expression is increased in a model of acute myocardial infarction in mice and in human subjects with acute coronary syndromes. Ectopic expression of miR-26a markedly induced EC cycle arrest and inhibited EC migration, sprouting angiogenesis, and network tube formation in matrigel, whereas blockade of miR-26a had the opposite effects. Mechanistic studies demonstrate that miR-26a inhibits the bone morphogenic protein/SMAD1 signaling pathway in ECs by binding to the SMAD1 3′-untranslated region, an effect that decreased expression of Id1 and increased p21 and p27. In zebrafish, miR-26a overexpression inhibited formation of the caudal vein plexus, a bone morphogenic protein-responsive process, an effect rescued by ectopic SMAD1 expression. In mice, miR-26a overexpression inhibited EC SMAD1 expression and exercise-induced angiogenesis. Furthermore, systemic intravenous administration of an miR-26a inhibitor, locked nucleic acid-anti-miR-26a, increased SMAD1 expression and rapidly induced robust angiogenesis within 2 days, an effect associated with reduced myocardial infarct size and improved heart function. CONCLUSIONS: These findings establish miR-26a as a regulator of bone morphogenic protein/SMAD1-mediated EC angiogenic responses, and that manipulating miR-26a expression could provide a new target for rapid angiogenic therapy in ischemic disease states.

Original languageEnglish (US)
Pages (from-to)1231-1241
Number of pages11
JournalCirculation Research
Volume113
Issue number11
DOIs
StatePublished - Nov 8 2013

Fingerprint

Physiologic Neovascularization
Pathologic Neovascularization
MicroRNAs
Endothelial Cells
Bone and Bones
Myocardial Infarction
Proteins
3' Untranslated Regions
Zebrafish
Acute Coronary Syndrome
Cell Cycle Checkpoints
Intravenous Administration
Embryonic Development
Cell Movement
Blood Vessels

Keywords

  • angiogenesis effect
  • endothelial cells
  • microRNAs
  • myocardial infarction

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. / Icli, Basak; Wara, A. K.M.; Moslehi, Javid; Sun, Xinghui; Plovie, Eva; Cahill, Meghan; Marchini, Julio F.; Schissler, Andrew; Padera, Robert F.; Shi, Jianru; Cheng, Hui Wen; Raghuram, Srilatha; Arany, Zoltan; Liao, Ronglih; Croce, Kevin; Macrae, Calum; Feinberg, Mark W.

In: Circulation Research, Vol. 113, No. 11, 08.11.2013, p. 1231-1241.

Research output: Contribution to journalArticle

Icli, B, Wara, AKM, Moslehi, J, Sun, X, Plovie, E, Cahill, M, Marchini, JF, Schissler, A, Padera, RF, Shi, J, Cheng, HW, Raghuram, S, Arany, Z, Liao, R, Croce, K, Macrae, C & Feinberg, MW 2013, 'MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling', Circulation Research, vol. 113, no. 11, pp. 1231-1241. https://doi.org/10.1161/CIRCRESAHA.113.301780
Icli, Basak ; Wara, A. K.M. ; Moslehi, Javid ; Sun, Xinghui ; Plovie, Eva ; Cahill, Meghan ; Marchini, Julio F. ; Schissler, Andrew ; Padera, Robert F. ; Shi, Jianru ; Cheng, Hui Wen ; Raghuram, Srilatha ; Arany, Zoltan ; Liao, Ronglih ; Croce, Kevin ; Macrae, Calum ; Feinberg, Mark W. / MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. In: Circulation Research. 2013 ; Vol. 113, No. 11. pp. 1231-1241.
@article{450d08ad97314943ba1d98db0b88282e,
title = "MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling",
abstract = "RATIONALE: The rapid induction and orchestration of new blood vessels are critical for tissue repair in response to injury, such as myocardial infarction, and for physiological angiogenic responses, such as embryonic development and exercise. OBJECTIVE: We aimed to identify and characterize microRNAs (miR) that regulate pathological and physiological angiogenesis. METHODS AND RESULTS: We show that miR-26a regulates pathological and physiological angiogenesis by targeting endothelial cell (EC) bone morphogenic protein/SMAD1 signaling in vitro and in vivo. MiR-26a expression is increased in a model of acute myocardial infarction in mice and in human subjects with acute coronary syndromes. Ectopic expression of miR-26a markedly induced EC cycle arrest and inhibited EC migration, sprouting angiogenesis, and network tube formation in matrigel, whereas blockade of miR-26a had the opposite effects. Mechanistic studies demonstrate that miR-26a inhibits the bone morphogenic protein/SMAD1 signaling pathway in ECs by binding to the SMAD1 3′-untranslated region, an effect that decreased expression of Id1 and increased p21 and p27. In zebrafish, miR-26a overexpression inhibited formation of the caudal vein plexus, a bone morphogenic protein-responsive process, an effect rescued by ectopic SMAD1 expression. In mice, miR-26a overexpression inhibited EC SMAD1 expression and exercise-induced angiogenesis. Furthermore, systemic intravenous administration of an miR-26a inhibitor, locked nucleic acid-anti-miR-26a, increased SMAD1 expression and rapidly induced robust angiogenesis within 2 days, an effect associated with reduced myocardial infarct size and improved heart function. CONCLUSIONS: These findings establish miR-26a as a regulator of bone morphogenic protein/SMAD1-mediated EC angiogenic responses, and that manipulating miR-26a expression could provide a new target for rapid angiogenic therapy in ischemic disease states.",
keywords = "angiogenesis effect, endothelial cells, microRNAs, myocardial infarction",
author = "Basak Icli and Wara, {A. K.M.} and Javid Moslehi and Xinghui Sun and Eva Plovie and Meghan Cahill and Marchini, {Julio F.} and Andrew Schissler and Padera, {Robert F.} and Jianru Shi and Cheng, {Hui Wen} and Srilatha Raghuram and Zoltan Arany and Ronglih Liao and Kevin Croce and Calum Macrae and Feinberg, {Mark W.}",
year = "2013",
month = "11",
day = "8",
doi = "10.1161/CIRCRESAHA.113.301780",
language = "English (US)",
volume = "113",
pages = "1231--1241",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling

AU - Icli, Basak

AU - Wara, A. K.M.

AU - Moslehi, Javid

AU - Sun, Xinghui

AU - Plovie, Eva

AU - Cahill, Meghan

AU - Marchini, Julio F.

AU - Schissler, Andrew

AU - Padera, Robert F.

AU - Shi, Jianru

AU - Cheng, Hui Wen

AU - Raghuram, Srilatha

AU - Arany, Zoltan

AU - Liao, Ronglih

AU - Croce, Kevin

AU - Macrae, Calum

AU - Feinberg, Mark W.

PY - 2013/11/8

Y1 - 2013/11/8

N2 - RATIONALE: The rapid induction and orchestration of new blood vessels are critical for tissue repair in response to injury, such as myocardial infarction, and for physiological angiogenic responses, such as embryonic development and exercise. OBJECTIVE: We aimed to identify and characterize microRNAs (miR) that regulate pathological and physiological angiogenesis. METHODS AND RESULTS: We show that miR-26a regulates pathological and physiological angiogenesis by targeting endothelial cell (EC) bone morphogenic protein/SMAD1 signaling in vitro and in vivo. MiR-26a expression is increased in a model of acute myocardial infarction in mice and in human subjects with acute coronary syndromes. Ectopic expression of miR-26a markedly induced EC cycle arrest and inhibited EC migration, sprouting angiogenesis, and network tube formation in matrigel, whereas blockade of miR-26a had the opposite effects. Mechanistic studies demonstrate that miR-26a inhibits the bone morphogenic protein/SMAD1 signaling pathway in ECs by binding to the SMAD1 3′-untranslated region, an effect that decreased expression of Id1 and increased p21 and p27. In zebrafish, miR-26a overexpression inhibited formation of the caudal vein plexus, a bone morphogenic protein-responsive process, an effect rescued by ectopic SMAD1 expression. In mice, miR-26a overexpression inhibited EC SMAD1 expression and exercise-induced angiogenesis. Furthermore, systemic intravenous administration of an miR-26a inhibitor, locked nucleic acid-anti-miR-26a, increased SMAD1 expression and rapidly induced robust angiogenesis within 2 days, an effect associated with reduced myocardial infarct size and improved heart function. CONCLUSIONS: These findings establish miR-26a as a regulator of bone morphogenic protein/SMAD1-mediated EC angiogenic responses, and that manipulating miR-26a expression could provide a new target for rapid angiogenic therapy in ischemic disease states.

AB - RATIONALE: The rapid induction and orchestration of new blood vessels are critical for tissue repair in response to injury, such as myocardial infarction, and for physiological angiogenic responses, such as embryonic development and exercise. OBJECTIVE: We aimed to identify and characterize microRNAs (miR) that regulate pathological and physiological angiogenesis. METHODS AND RESULTS: We show that miR-26a regulates pathological and physiological angiogenesis by targeting endothelial cell (EC) bone morphogenic protein/SMAD1 signaling in vitro and in vivo. MiR-26a expression is increased in a model of acute myocardial infarction in mice and in human subjects with acute coronary syndromes. Ectopic expression of miR-26a markedly induced EC cycle arrest and inhibited EC migration, sprouting angiogenesis, and network tube formation in matrigel, whereas blockade of miR-26a had the opposite effects. Mechanistic studies demonstrate that miR-26a inhibits the bone morphogenic protein/SMAD1 signaling pathway in ECs by binding to the SMAD1 3′-untranslated region, an effect that decreased expression of Id1 and increased p21 and p27. In zebrafish, miR-26a overexpression inhibited formation of the caudal vein plexus, a bone morphogenic protein-responsive process, an effect rescued by ectopic SMAD1 expression. In mice, miR-26a overexpression inhibited EC SMAD1 expression and exercise-induced angiogenesis. Furthermore, systemic intravenous administration of an miR-26a inhibitor, locked nucleic acid-anti-miR-26a, increased SMAD1 expression and rapidly induced robust angiogenesis within 2 days, an effect associated with reduced myocardial infarct size and improved heart function. CONCLUSIONS: These findings establish miR-26a as a regulator of bone morphogenic protein/SMAD1-mediated EC angiogenic responses, and that manipulating miR-26a expression could provide a new target for rapid angiogenic therapy in ischemic disease states.

KW - angiogenesis effect

KW - endothelial cells

KW - microRNAs

KW - myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84888131596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888131596&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.113.301780

DO - 10.1161/CIRCRESAHA.113.301780

M3 - Article

C2 - 24047927

AN - SCOPUS:84888131596

VL - 113

SP - 1231

EP - 1241

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 11

ER -